Insider buying last 90 days
$493Kin 2 open-market purchases
| Filed | Insider | Type | Value |
|---|---|---|---|
| Aug 18 | BIENAIME JEAN JACQUES director | Purchase | $270K |
| Aug 18 | BIENAIME JEAN JACQUES director | Purchase | $222K |
From Form 4 filings, dated to when each was filed.
Gekko Brief
AI summaryThis week’s attention centers on continued analyst coverage of Ascendis Pharma, with Cantor Fitzgerald reaffirming an “Overweight” rating on 28 September with a $300.00 price target, following Morgan Stanley’s reiterated Buy rating and $273 target on 22 September. A separate analysis piece the same day highlighted the company’s TransCon-based therapy pipeline, citing products SKYTROFA and YORV alongside a market capitalization of $15.57 billion and revenue growth of 114.70%. These items concern ongoing sell-side sentiment and product-driven growth narratives rather than new corporate events.
ASND closed at $230.05, up 2% on the day, sitting between its 50-day average of $250.71 and 200-day average of $235.24, reflecting a mixed trend. The stock’s one-month return stands at -7.7% and three-month at -12.8%, while the one-year return is 21.2%. The GekkoIndex reads 66, placing it in the Accumulation zone. Price sits 16.2% below Gekko Fair Value of $274.55.
Over the next 20 trading days, the next earnings date falls on 11 November, 43 days away, outside a typical holding window. Smart money activity includes 2 insider purchases totaling $492,654 within the last 90 days, with no billionaire holders currently recorded. Seasonality over the past 5 years shows an average -3% move across this period, with gains occurring in 2 of those years. The consensus among 18 analysts remains a unanimous Buy, with a consensus target of $310.30, representing 34.9% upside from current levels.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Ascendis Pharma price vs fair value
Close $230.05200-day averageGekko Fair Value $274.55
Ascendis Pharma quick facts
- Market cap
- $14.29B
- P/E ratio
- 17.7
- Forward P/E
- 19.8
- EPS, TTM
- $12.72
- Revenue, TTM
- $1.05B
- Profit margin
- 70.9%
- Dividend yield
- —
- Beta
- 0.49
- Volume
- 747,504 avg 885,031
- 1-year return
- +21.2%
- Typical daily move
- ±4.6%
- Typical 20-day move
- ±5.9%
- 50-day average
- $250.71
- 200-day average
- $235.24
- Next earnings
- Nov 11 after close
- Shares outstanding
- 65.78M
Ascendis Pharma swing-trade checklist
Ascendis Pharma scores 4 supportive, 1 mixed and 1 headwind across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive1 mixed1 headwind
- Trendmixed
Averages disagree
Close $230.05 sits between the 50-day ($250.71) and 200-day ($235.24) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
66, Accumulation
Reading 66 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
16.2% below
Price is 16.2% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneysupportive
Leans bullish
Last 90 days: 2 open-market insider purchases.
See smart money - Earnings risksupportive
Reports in 43 days
Next report Nov 11, 2026, 43 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−3.0% on average
From this point in the calendar, the next 20 trading days averaged −3% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Ascendis Pharma stock chart and price history
Ascendis Pharma closed at $230.05 on Sep 28, 2026, +21.2% over the past year, inside a 52-week range of $186.05 to $282.15.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −7.7%
- 3 months
- −12.8%
- 6 months
- +6.0%
- 1 year
- +21.2%
The full ASND chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open ASND in Gekko
Follow Ascendis Pharma through every session
Put ASND on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track ASND in GekkoFree for 7 days. No credit card required.
About Ascendis Pharma
Ascendis Pharma develops medical treatments aimed at serious conditions where existing options remain limited. Its approved product, SKYTROFA, treats growth hormone deficiency. Beyond this, the company is best known for its work using TransCon technology to build a broader pipeline of experimental therapies.
That pipeline includes a growth hormone candidate being studied for pediatric patients in Japan and for adults with the same deficiency, along with a parathyroid hormone treatment for adults with hypoparathyroidism and a compound targeting pediatric achondroplasia. The company is also working on a therapy delivered directly into tumors using a toll-like receptor agonist, and a separate treatment designed for systemic delivery based on interleukin-2 biology. Together these programs form the core of how Ascendis Pharma builds out its treatment offerings beyond its marketed product.
The company was established in 2006 and is headquartered in Hellerup, Denmark. Its shares trade under the ticker ASND.
- Sector
- Health technology
- Website
- ascendispharma.com
Ascendis Pharma GekkoIndex: the smart money zone
Ascendis Pharma’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 66, in the Accumulation zone, down 1.5 points over five sessions.
66Accumulation
Down 1.5 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 16 | +11.1% | +12.5% | ||
| Accumulation (current zone) | 169 | +2.3% | +6.6% | ||
| Neutral | 422 | −0.6% | +0.1% | ||
| Distribution | 18 | +0.1% | −2.2% | ||
| Selling | 0 | Not available | |||
Average ASND share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the ASND price, zone by zone.Track ASND in Gekko
Is Ascendis Pharma stock overvalued? Gekko Fair Value
Ascendis Pharma trades 16.2% below Gekko Fair Value of $274.55, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Ascendis Pharma shares are worth, recalculated every trading day.
$274.55
Gekko Fair Value, Sep 29, 2026
16.2% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open ASND in Gekko
Ascendis Pharma insider and Congress trading
Insiders filed 2 open-market purchases in Ascendis Pharma worth $493K, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in ASND were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for ASND, plotted on the chart in Gekko.Open ASND in Gekko
Hedge funds and billionaires quarter ended Jun 30
0of the funds Gekko tracks hold ASND.
0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Ascendis Pharma earnings: next date and track record
Ascendis Pharma reports on Nov 11, 2026, after the close (43 days away), and beat the EPS estimate in 3 of its last 8 reports.
Next earnings report
Nov 11, 2026
Expected after the close, 43 days away
- EPS estimate
- $1.13
- Revenue estimate
- $475.5M
3 of 8reports beat the EPS estimate
±4.6%average move across the report
7 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | $3.29 est $0.78 | — | +4.6% |
| May 7, 2026 | $0.27 est $0.43 | $284.9M est $308.9M | +1.2% |
| Feb 11, 2026 | −$0.55 est −$0.24 | $344.8M est $292.3M | −2.7% |
| Nov 12, 2025 | −$1.00 est −$0.12 | $250.2M est $302.6M | +2.6% |
| Aug 7, 2025 | −$0.93 est −$1.42 | $186.1M est $233.1M | +4.9% |
| May 1, 2025 | −$1.58 est −$1.51 | $110.7M est $153.5M | +1.0% |
| Feb 12, 2025 | −$0.64 est −$1.17 | $180.1M est $125.4M | +19.2% |
| Nov 14, 2024 | −$1.72 est −$1.46 | — | +0.4% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Ascendis Pharma stock forecast and analyst price targets
Analysts’ average 12-month price target for Ascendis Pharma is $310.30, +34.9% from the last close, from 18 firms rating the stock in the last 90 days.
$310.30consensus 12-month target, +34.9% from the last close
Now $230.05Avg $310.30
Low $273High $360
Each firm’s latest rating in the last 90 days: 18 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 28 | Morgan Stanley | $273 | +18.7% |
| Sep 25 | Cantor Fitzgerald | $300 | +30.4% |
| Sep 21 | Morgan Stanley | $273 | +18.7% |
| Sep 16 | Wedbush | $327 | +42.1% |
| Sep 16 | H.C. Wainwright | $344 | +49.5% |
+6.6%average 20-day move after past Accumulation readings
−3.0%average move over the next 20 trading days in the last 5 years
±4.6%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Ascendis Pharma seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, Ascendis Pharma averaged −3.0% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +4.3% | 3 of 5 |
| Next 10 trading days | +2.3% | 3 of 5 |
| Next 15 trading days | −2.1% | 2 of 5 |
| Next 20 trading days | −3.0% | 2 of 5 |
| Next 30 trading days | +1.6% | 2 of 5 |
For scale, ASND’s typical 20-trading-day move in either direction is about 5.9%.
Ascendis Pharma market cap and key statistics
Ascendis Pharma’s market cap is $14.29B, with a P/E ratio of 17.7 and revenue of $1.05B over the last twelve months.
Valuation
- Market cap
- $14.29B
- P/E ratio
- 17.7
- Forward P/E
- 19.8
- EPS, TTM
- $12.72
- Gekko Fair Value
- $274.55
Trading
- Volume
- 747,504
- Avg volume, 20 days
- 885,031
- 52-week high
- $282.15
- 52-week low
- $186.05
- Shares outstanding
- 65.78M
Financials
- Revenue, TTM
- $1.05B
- Profit margin
- 70.9%
- Return on equity
- 118.8%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 0.49
- Typical daily move
- ±4.6%
- Typical 20-day move
- ±5.9%
Ascendis Pharma stock news this week
Coverage of Ascendis Pharma this week reads positive: 2 positive, 1 neutral and 0 negative headlines.
- Ascendis Pharma A/S’s (ASND) “Overweight” Rating Reaffirmed at Cantor FitzgeraldDefense World, Sep 28
- Long term debt to total equity ratio of Ascendis Pharma A/S – FWB:A710TradingView, Sep 25
- Ascendis Pharma A/S (ASND) Stock Analysis: Exploring a Potential 31.52% Upside in Biotech SectorDirectorsTalk Interviews, Sep 22
- Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $273Moomoo, Sep 22
Ascendis Pharma stock FAQ
What is Ascendis Pharma’s market cap?
Ascendis Pharma’s market cap is $14.29B at the Sep 28, 2026 close of $230.05, with 65.78M shares outstanding. The shares trade on a P/E ratio of 17.7.
What is the Ascendis Pharma stock forecast?
The consensus analyst 12-month price target for Ascendis Pharma is $310.30, +34.9% from the last close. Of the 18 firms that rated the stock in the last 90 days, 18 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Ascendis Pharma stock overvalued or undervalued?
On Gekko’s estimate Ascendis Pharma is undervalued: the Sep 28, 2026 close of $230.05 is 16.2% below Gekko Fair Value of $274.55. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Ascendis Pharma report earnings next?
Ascendis Pharma is expected to report on Nov 11, 2026, after the market closes (43 days away). Analysts expect earnings of $1.13 per share on revenue of $475.5M. Ascendis Pharma beat the earnings estimate in 3 of its last 8 reports, moving 4.6% on average across the report.
What is Ascendis Pharma’s 52-week high and low?
Ascendis Pharma’s 52-week high is $282.15 and its 52-week low is $186.05; it closed at $230.05 on Sep 28, 2026, +21.2% over the past year.
Is Ascendis Pharma stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (gekkoindex, fair value, smart money and earnings risk), 1 as mixed (trend) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Ascendis Pharma the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.